Martin Shkreli Publishes Bull Case for Photonic Computing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 06 2026
0mins
Source: Benzinga
- Photonic Computing Potential: Martin Shkreli argues in his Substack essay that photonic computing can perform matrix operations using light instead of electrical signals, potentially reducing computation time from cubic to near-linear, which could have significant market implications if realized.
- Investment and Advisory Role: Shkreli has been a strategic advisor to Q/C Technologies Inc. since December, emphasizing his confidence in photonic computing, which may attract more investor interest in this emerging field.
- Market Reaction and Risks: While Shkreli's insights could lead to a reevaluation of market predictions for companies like Nvidia, skepticism remains regarding the near-term threat of photonic computing, indicating cautious investor sentiment towards this technology.
- Company Financials: QCLS is facing financial challenges with a trailing twelve-month net loss of approximately $23.4 million and minimal revenue, and although its stock rose 27% on Thursday, it remains significantly below its 52-week high, reflecting uncertainty about its future prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVDA
Wall Street analysts forecast NVDA stock price to rise
41 Analyst Rating
39 Buy
1 Hold
1 Sell
Strong Buy
Current: 214.250
Low
200.00
Averages
264.97
High
352.00
Current: 214.250
Low
200.00
Averages
264.97
High
352.00
About NVDA
NVIDIA Corporation is an artificial intelligence (AI) infrastructure company. The Company is engaged in accelerated computing to help solve the challenging computational problems. Its segments include Compute & Networking and Graphics. The Compute & Networking segment includes its Data Center accelerated computing and networking platforms and AI solutions and software, and automotive platforms and autonomous and electric vehicle solutions, including software. The Graphics segment includes GeForce GPUs for gaming and personal computers (PCs), and Quadro/NVIDIA RTX GPUs for enterprise workstation graphics. Its technology stack includes the foundational NVIDIA CUDA development platform that runs on all NVIDIA GPUs, as well as hundreds of domain-specific software libraries, frameworks, algorithms, software development kits (SDKs), and application programming interfaces (APIs). Its platforms address four markets, which include Data Center, Gaming, Professional Visualization, and Automotive.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NVIDIA Launches DSX Platform to Redefine AI Factories
- Platform Innovation: NVIDIA's launch of the DSX platform integrates open-source and modular software, providing a comprehensive playbook for AI factory design, deployment, and operations, aimed at accelerating production and enhancing overall operational efficiency by reducing token costs.
- New Software Release: The DSX MaxLPS software combines 45-degree liquid cooling with in-rack optimization technologies, enabling a 40% increase in token performance within a fixed power budget, significantly lowering operational costs and improving GPU utilization.
- Ecosystem Expansion: NVIDIA is partnering with leading Taiwanese system manufacturers to drive the development of the DSX ecosystem, ensuring extreme co-design for AI factories, facilitating rapid deployment and operation on a global scale.
- Market Responsiveness: The introduction of the DSX platform allows infrastructure builders to simulate the entire factory before investment, validating performance to reduce risk and enhance market responsiveness, further solidifying NVIDIA's leadership position in the AI sector.
See More
Eli Lilly Poised for Nvidia-Style Growth Surge
- Market Leadership: Eli Lilly currently holds a 60% share of the U.S. GLP-1 drug market, significantly surpassing former leader Novo Nordisk, showcasing its strong competitive position in the rapidly growing weight loss drug market, which is projected to approach $100 billion by the end of the decade.
- Innovation-Driven Growth: The recent launch of Lilly's weight loss drug Zepbound and strong results from late-stage clinical trials indicate that the company's ongoing investment in innovation will bolster its market leadership, further solidifying its advantage in the weight loss sector.
- Strong Stock Performance: Lilly's stock surged over 18% in the past month, surpassing the $1,000 mark, reflecting investor confidence in its weight loss portfolio, especially following the approval of its oral weight loss drug Foundayo, which has significantly enhanced market expectations for future growth.
- Diversified Product Portfolio: Lilly is actively developing a broad portfolio of weight loss drugs, including both oral and injectable options, and with the positive phase 3 trial data for retatrutide, the company is poised to expand its product line further in the coming years, maintaining its leading position in a competitive market.
See More
Three AI Stocks Worth Buying This Month
- Nvidia's Strong Growth: Nvidia reported an impressive 85% year-over-year revenue increase in its latest earnings report, with analysts forecasting a 96% revenue growth for the next quarter, indicating sustained demand for its GPUs and a potential stock rally in the second half of 2026, making it an excellent buy in June.
- Meta's Advertising Revenue Recovery: Despite a 4% decline in stock price, Meta's latest quarter saw a 33% revenue increase driven by AI enhancements in ad impressions and conversions, with a current P/E ratio below 20, presenting a compelling investment opportunity as the stock is expected to rebound throughout the year.
- Nebius's Explosive Growth: Nebius's stock has surged 170% this year, with Q1 revenue soaring 684% year-over-year, and projections of 550% revenue growth this year and 219% next year, as the company focuses on AI computing data centers, showcasing significant market potential despite not yet being profitable.
- Sustained Demand in AI Market: With increasing demand for AI computing, Nebius is heavily investing to capture market share, and while execution risks remain, its optimistic growth outlook suggests a continued upward trend through 2026 and beyond.
See More
Eli Lilly Gains Approval for New Drug, Strengthening Weight Loss Market Leadership
- Market Leadership: Eli Lilly currently holds a 60% share of the U.S. GLP-1 drug market, significantly surpassing former leader Novo Nordisk, demonstrating its strong competitive position in the rapidly growing weight loss drug sector.
- New Product Launch: Lilly received approval for its oral weight loss drug Foundayo in April, with early trends showing promising results, further enriching its weight loss portfolio and positioning the company advantageously in a market approaching $100 billion.
- Successful Clinical Trials: Recently, Lilly reported positive phase 3 trial data for its candidate retatrutide, which, if successful, will complement its existing oral and injectable drugs to create a comprehensive weight loss portfolio catering to patients with varying obesity levels.
- Strong Stock Performance: Lilly's stock surged over 18% in the past month, surpassing $1,000, as investors express confidence in its high growth potential in the weight loss market, potentially indicating a growth trajectory similar to Nvidia's.
See More
Investment Opportunities in AI Stocks
- Nvidia's Strong Performance: Nvidia recently reported an impressive 85% year-over-year revenue growth, with expectations for a 96% increase in the next quarter, indicating sustained demand for its GPUs and significant long-term growth potential, which could lead to a stock price rally in the second half of 2026.
- Meta's Recovery Potential: Despite a 4% decline in stock price this year, Meta's latest quarterly revenue surged by 33%, driven by increased ad impressions and conversions, suggesting continued growth potential supported by a strong ad market and the rollout of new AI features, with a current P/E ratio below 20, indicating investment value.
- Nebius's Rapid Growth: Nebius's stock has soared 170% this year, with a staggering 684% year-over-year revenue increase in Q1, and projections of 550% revenue growth this year and 219% next year, highlighting its strong demand in the AI computing market and rapid market share expansion.
- Investor Focus on AI Stocks: Although Nvidia was not included in The Motley Fool's list of top investment stocks, its leadership in the AI sector and robust financial performance make it a noteworthy investment choice, especially against the backdrop of growing demand for AI computing.
See More
Nvidia's New Chip Plans Ignite Software Stock Surge
- Software Stock Surge: Following Nvidia CEO Jensen Huang's announcement of the new N1X processor, software stocks surged on the first trading day of June, with ServiceNow's shares soaring 14.4%, indicating strong market enthusiasm for new technology.
- Competitive Pressure: Nvidia's expansion into the PC chip market has led to a nearly 6% drop in rival Intel's stock, reflecting market confidence in Nvidia's new products and concerns about Intel's future outlook.
- Korean Tech Stock Performance: Boosted by rising South Korean tech stocks, the KOSPI index gained 3.7%, with LG Electronics shares up 29.9% and Samsung Electronics rising about 10.1%, showcasing robust regional market performance.
- Potential Collaboration Opportunities: Jensen Huang is expected to meet with Samsung and LG executives later this week to discuss collaboration in AI and robotics, potentially paving the way for future technological innovations and market expansion.
See More
NVIDIA Launches DSX Platform to Redefine AI Factories
- Platform Innovation: NVIDIA's launch of the DSX platform integrates open-source and modular software, providing a comprehensive playbook for AI factory design, deployment, and operations, aimed at accelerating production and enhancing overall operational efficiency by reducing token costs.
- New Software Release: The DSX MaxLPS software combines 45-degree liquid cooling with in-rack optimization technologies, enabling a 40% increase in token performance within a fixed power budget, significantly lowering operational costs and improving GPU utilization.
- Ecosystem Expansion: NVIDIA is partnering with leading Taiwanese system manufacturers to drive the development of the DSX ecosystem, ensuring extreme co-design for AI factories, facilitating rapid deployment and operation on a global scale.
- Market Responsiveness: The introduction of the DSX platform allows infrastructure builders to simulate the entire factory before investment, validating performance to reduce risk and enhance market responsiveness, further solidifying NVIDIA's leadership position in the AI sector.
See More
Eli Lilly Poised for Nvidia-Style Growth Surge
- Market Leadership: Eli Lilly currently holds a 60% share of the U.S. GLP-1 drug market, significantly surpassing former leader Novo Nordisk, showcasing its strong competitive position in the rapidly growing weight loss drug market, which is projected to approach $100 billion by the end of the decade.
- Innovation-Driven Growth: The recent launch of Lilly's weight loss drug Zepbound and strong results from late-stage clinical trials indicate that the company's ongoing investment in innovation will bolster its market leadership, further solidifying its advantage in the weight loss sector.
- Strong Stock Performance: Lilly's stock surged over 18% in the past month, surpassing the $1,000 mark, reflecting investor confidence in its weight loss portfolio, especially following the approval of its oral weight loss drug Foundayo, which has significantly enhanced market expectations for future growth.
- Diversified Product Portfolio: Lilly is actively developing a broad portfolio of weight loss drugs, including both oral and injectable options, and with the positive phase 3 trial data for retatrutide, the company is poised to expand its product line further in the coming years, maintaining its leading position in a competitive market.
See More
Three AI Stocks Worth Buying This Month
- Nvidia's Strong Growth: Nvidia reported an impressive 85% year-over-year revenue increase in its latest earnings report, with analysts forecasting a 96% revenue growth for the next quarter, indicating sustained demand for its GPUs and a potential stock rally in the second half of 2026, making it an excellent buy in June.
- Meta's Advertising Revenue Recovery: Despite a 4% decline in stock price, Meta's latest quarter saw a 33% revenue increase driven by AI enhancements in ad impressions and conversions, with a current P/E ratio below 20, presenting a compelling investment opportunity as the stock is expected to rebound throughout the year.
- Nebius's Explosive Growth: Nebius's stock has surged 170% this year, with Q1 revenue soaring 684% year-over-year, and projections of 550% revenue growth this year and 219% next year, as the company focuses on AI computing data centers, showcasing significant market potential despite not yet being profitable.
- Sustained Demand in AI Market: With increasing demand for AI computing, Nebius is heavily investing to capture market share, and while execution risks remain, its optimistic growth outlook suggests a continued upward trend through 2026 and beyond.
See More
Eli Lilly Gains Approval for New Drug, Strengthening Weight Loss Market Leadership
- Market Leadership: Eli Lilly currently holds a 60% share of the U.S. GLP-1 drug market, significantly surpassing former leader Novo Nordisk, demonstrating its strong competitive position in the rapidly growing weight loss drug sector.
- New Product Launch: Lilly received approval for its oral weight loss drug Foundayo in April, with early trends showing promising results, further enriching its weight loss portfolio and positioning the company advantageously in a market approaching $100 billion.
- Successful Clinical Trials: Recently, Lilly reported positive phase 3 trial data for its candidate retatrutide, which, if successful, will complement its existing oral and injectable drugs to create a comprehensive weight loss portfolio catering to patients with varying obesity levels.
- Strong Stock Performance: Lilly's stock surged over 18% in the past month, surpassing $1,000, as investors express confidence in its high growth potential in the weight loss market, potentially indicating a growth trajectory similar to Nvidia's.
See More
Investment Opportunities in AI Stocks
- Nvidia's Strong Performance: Nvidia recently reported an impressive 85% year-over-year revenue growth, with expectations for a 96% increase in the next quarter, indicating sustained demand for its GPUs and significant long-term growth potential, which could lead to a stock price rally in the second half of 2026.
- Meta's Recovery Potential: Despite a 4% decline in stock price this year, Meta's latest quarterly revenue surged by 33%, driven by increased ad impressions and conversions, suggesting continued growth potential supported by a strong ad market and the rollout of new AI features, with a current P/E ratio below 20, indicating investment value.
- Nebius's Rapid Growth: Nebius's stock has soared 170% this year, with a staggering 684% year-over-year revenue increase in Q1, and projections of 550% revenue growth this year and 219% next year, highlighting its strong demand in the AI computing market and rapid market share expansion.
- Investor Focus on AI Stocks: Although Nvidia was not included in The Motley Fool's list of top investment stocks, its leadership in the AI sector and robust financial performance make it a noteworthy investment choice, especially against the backdrop of growing demand for AI computing.
See More
Nvidia's New Chip Plans Ignite Software Stock Surge
- Software Stock Surge: Following Nvidia CEO Jensen Huang's announcement of the new N1X processor, software stocks surged on the first trading day of June, with ServiceNow's shares soaring 14.4%, indicating strong market enthusiasm for new technology.
- Competitive Pressure: Nvidia's expansion into the PC chip market has led to a nearly 6% drop in rival Intel's stock, reflecting market confidence in Nvidia's new products and concerns about Intel's future outlook.
- Korean Tech Stock Performance: Boosted by rising South Korean tech stocks, the KOSPI index gained 3.7%, with LG Electronics shares up 29.9% and Samsung Electronics rising about 10.1%, showcasing robust regional market performance.
- Potential Collaboration Opportunities: Jensen Huang is expected to meet with Samsung and LG executives later this week to discuss collaboration in AI and robotics, potentially paving the way for future technological innovations and market expansion.
See More
